Personalized dosimetry assessment of [ 177 Lu]Lu-PSMA-617 radioligand therapy in the management of metastatic castration-resistant prostate cancer

This study indicates that the ADs of OARs and tumoral lesions from [¹⁷⁷Lu]Lu-PSMA-617 RLT in patients with mCRPC are consistent with existing literature. The dosimetry findings suggest that increasing the administered activity of [¹⁷⁷Lu]Lu-PSMA-617 RLT is feasible and does not pose a significant risk of adverse effects on OARs, as supported by our data. However, to validate the safety and efficacy of higher doses, further clinical follow-up studies are recommended.